Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

EVGN vs CLYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–0 Matrix Metrics)

CLYM Overall Winner 6-Pillar Tally: EVGN 1 – 2 CLYM (3 Tie) Matrix Metrics: EVGN 0 – 7 CLYM

As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas CLYM carries 51.0/100 (HOLD) at $9.78 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: EVGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.4); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVGN vs CLYM
EVGN NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap $6.0M
TTM Revenue $1.7M
Forward P/E N/M
Beta / 30D Vol 1.37β · 138% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 42.0 Fund 44.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $0.36 · SMA50: $0.40
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.78
-1.61% 1D
Market Cap $583.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.52β · 112% Vol
Unified Composite Score
51.0 / 100 HOLD
Tech 65.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 43
RSI-14: 43.4 · SMA20: $10.22 · SMA50: $11.34

6-Pillar Scorecard Institutional Category Breakdown (EVGN 1 – 2 CLYM)

Columns: Metric · EVGN · CLYM
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CLYM
Revenue Growth (YoY) -60.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.7M N/A
Market Cap $6.0M $583.9M
3. Profitability & Quality CLYM
Gross Margin -67.6% N/A
Operating Margin -858.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -182.8% -29.3%
4. Balance Sheet & Cash Flow EVGN
Cash Generation (TTM) -$11M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.5M Net Cash $3.95 Book/Sh · -29.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVGN (0) vs CLYM (7)
Institutional Metric EVGN CLYM Criterion Row Edge
Market Capitalization
Scale
$6.0M $583.9M Larger Scale CLYM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-60.7% +0.0% Higher Growth CLYM
Operating Margin (TTM)
Profitability
-858.2% 0.0% Higher Margin CLYM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-182.8% -29.3% Higher ROE CLYM
52-Week Range Position
Momentum
9% ($0–$1) 49% ($2–$18) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
1.37β · 138% Vol 1.52β · 112% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 51.0 / 100 (HOLD) Higher Composite CLYM
Trailing 12M Revenue (USD)
Operating Scale
$1.7M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-67.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M ($6.5M Net Cash) N/A ($3.95 Book/Sh · -29.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLYM +8.09 pp
EVGN: -7.58% · CLYM: +0.51%
3M Horizon EVGN +0.2 pp
EVGN: -43.4% · CLYM: -43.6%
6M Horizon CLYM +55.64 pp
EVGN: -54.29% · CLYM: +1.35%
1Y Horizon CLYM +486.63 pp
EVGN: -71.89% · CLYM: +414.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVGN vs CLYM. Trailing 12-month operating profitability (EVGN -858.2% vs CLYM 0.0%) and valuation multiples (EVGN N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EVGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.7M
Gross Margin-67.6%
Op. Margin-858.2%
ROE / Fwd P/E-182.8% · N/M
CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EVGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.0M market capitalization and -858.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $583.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EVGN vs CLYM Key Questions & Quantitative Answers

As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas CLYM carries 51.0/100 (HOLD) at $9.78 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: EVGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.4); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLYM leads the Growth & Scale pillar: EVGN posts -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EVGN generates $1.7M in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, EVGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.

EVGN and CLYM trade at balanced relative valuation multiples. EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVGN (-182.8% ROE) versus CLYM (-29.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.